103516-75-2C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1.O=C(O)/C=C\C(=O)OJDZOTSLZMQDFLG-BTJKTKAUSA-NPERHEXILINE MALEATE is a small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974. It was withdrawn in at least one region.
103516-75-2、103516-76-3、6724-53-4White Solid
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
Drug-Induced Liver Injury Severity and Toxicity (DILIst)
perhexiline maleate
DILI Positive
DOI:10.1016/j.drudis.2019.09.022
개요Perhexiline is a carnitine palmitoyltransferase 1 (CPT1) and CPT2 inhibitor that was originally developed as an anti-anginal drug in the 1970s. It inhibits rat heart and liver CPT1 (IC50 = 77 and 148 μM, respectively) and rat heart CPT2 (IC50 = 79 μM). Inhibition of CPT reduces uptake of long-chain fatty acids into the mitochondria, thereby shifting cellular metabolism from β-oxidation to glycolysis. Perhexilin inhibits mTORC1 signaling at 10 μM and induces autophagy ~7-fold at a concentration of 10 μM in MCF-7 cells.
용도PERHEXILINE MALEATE SALT is a Vasodilator, used in treatments for angina.
일반 설명Perhexiline maleate regulatescoronary vasodilatation and blocks exercise-induced tachycardia. It is used to treat angina pectoris and variant angina. Perhexiline maleate functions as a cardiac metabolic agent. It is associated with peripheral neuropathy, high intracranial pressure withpapilledemaand proximal myopathy.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…
DTXSID1021114CHEMBL1334033CHEBI:232991